To achieve better anti-tumour activity, PARP inhibitors have been combined with certain DNA-damaging agents, such as radiotherapy or chemotherapy agents, for the treatment of cancer46, 47, 48, 49, 50. The gene discussed is PARP1; the disease is neoplasm.